RISKA: Respiratory Irritability With School Kids With/Without Asthma - Assessment of Methacholine Responsiveness in Pediatric Asthma: A Comparative Study With Healthy Controls

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed. At the study visit, a methacholine challenge test measuring airway hyperresponsiveness and an exhaled nitric oxide measurement are performed. The effect of medication intensification in asthma patients is further assessed through a telephone interview 1-2 months after the medication adjustment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Maximum Age: 15
Healthy Volunteers: t
View:

• • Aged 7-15 years, both sexes

‣ No diagnosis of asthma in childhood

⁃ No inhaled asthma medication during the previous 2 years

⁃ No wheezing or shortness of breath during the previous 2 years

⁃ Written informed consent from the participant and guardian

• Aged 7-15 years, both sexes

• Physician-diagnosed asthma (ICD-10 codes J45.0/J45.1/J45.9)

• Inhaled corticosteroid treatment for at least 6 months

• Either:

‣ Well-controlled asthma (c-ACT/ACT score ≥20) and no clinical need to intensify medication, or

⁃ Poorly controlled asthma with physician-confirmed need for intensified asthma medication

Locations
Other Locations
Finland
HUS Skin and Allergy Hospital
RECRUITING
Helsinki
Contact Information
Primary
Janne Burman, PhD, MD
janne.burman@hus.fi
+358406517912
Backup
Anssi Koivuselkä, Nurse
anssi.koivuselka@hus.fi
Time Frame
Start Date: 2024-11-06
Estimated Completion Date: 2027-12
Participants
Target number of participants: 260
Treatments
Controlled Asthma
Children with asthma without need to intensify asthma treatment
Unocontrolled Asthma
Children with asthma and need to intensify their asthma treatment
Controlls
Children without asthmatic symptoms and medication
Related Therapeutic Areas
Sponsors
Leads: Helsinki University Central Hospital

This content was sourced from clinicaltrials.gov